BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 10092645)

  • 1. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide].
    Mahajan S; Ghosh S; Sudbeck EA; Zheng Y; Downs S; Hupke M; Uckun FM
    J Biol Chem; 1999 Apr; 274(14):9587-99. PubMed ID: 10092645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anti-leukemic Bruton's tyrosine kinase inhibitor alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism.
    Uckun FM; Vassilev A; Bartell S; Zheng Y; Mahajan S; Tibbles HE
    Leuk Lymphoma; 2003 Sep; 44(9):1569-77. PubMed ID: 14565661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase.
    Uckun FM; Zheng Y; Cetkovic-Cvrlje M; Vassilev A; Lisowski E; Waurzyniak B; Chen H; Carpenter R; Chen CL
    Clin Cancer Res; 2002 May; 8(5):1224-33. PubMed ID: 12006542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity.
    van den Akker E; van Dijk TB; Schmidt U; Felida L; Beug H; Löwenberg B; von Lindern M
    Biol Chem; 2004 May; 385(5):409-13. PubMed ID: 15196000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical toxicity and pharmacokinetics of the Bruton's tyrosine kinase-targeting anti-leukemic drug candidate, alpha-cyano-beta-hydroxy-beta-methyl-N- (2,5-dibromophenyl) propenamide (LFM-A13).
    Uckun FM; Tibbles H; Venkatachalam T; DuMez D; Erbeck D
    Arzneimittelforschung; 2007; 57(1):31-46. PubMed ID: 17341007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).
    Uckun FM; Dibirdik I; Qazi S; Vassilev A; Ma H; Mao C; Benyumov A; Emami KH
    Bioorg Med Chem; 2007 Jan; 15(2):800-14. PubMed ID: 17098432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase.
    Ghosh S; Zheng Y; Jun X; Mahajan S; Mao C; Sudbeck EA; Uckun FM
    Clin Cancer Res; 1999 Dec; 5(12):4264-72. PubMed ID: 10632369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo chemosensitizing activity of LFM-A13, a dual-function inhibitor of Bruton's tyrosine kinase and polo-like kinases, against human leukemic B-cell precursors.
    Uckun F; Dibirdik I; Sarkissian A; Qazi S
    Arzneimittelforschung; 2011; 61(4):252-9. PubMed ID: 21650085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model.
    Cetkovic-Cvrlje M; Uckun FM
    Br J Haematol; 2004 Sep; 126(6):821-7. PubMed ID: 15352986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large-scale synthesis of GMP grade alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13), a new anti-cancer drug candidate.
    DuMez D; Venkatachalam TK; Uckun FM
    Arzneimittelforschung; 2007; 57(3):155-63. PubMed ID: 17469650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-cyano-N-(2,5-dibromophenyl)-beta-hydroxybut-2-enamide.
    Ghosh S; Uckun FM
    Acta Crystallogr C; 1999 Aug; 55 ( Pt 8)():1364-5. PubMed ID: 10483706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous use of erythropoietin and LFM-A13 as a new therapeutic approach for colorectal cancer.
    Tankiewicz-Kwedlo A; Hermanowicz JM; Domaniewski T; Pawlak K; Rusak M; Pryczynicz A; Surazynski A; Kaminski T; Kazberuk A; Pawlak D
    Br J Pharmacol; 2018 Mar; 175(5):743-762. PubMed ID: 29160911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton's tyrosine kinase as a new therapeutic target.
    Uckun FM; Tibbles HE; Vassilev AO
    Anticancer Agents Med Chem; 2007 Nov; 7(6):624-32. PubMed ID: 18045057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo toxicity and antithrombotic profile of the oral formulation of the antileukemic agent, LFM-A13-F.
    Tibbles HE; Samuel P; Erbeck D; Mahajan S; Uckun FM
    Arzneimittelforschung; 2004; 54(6):330-9. PubMed ID: 15281619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents.
    Sudbeck EA; Liu XP; Narla RK; Mahajan S; Ghosh S; Mao C; Uckun FM
    Clin Cancer Res; 1999 Jun; 5(6):1569-82. PubMed ID: 10389946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotactic factor-induced recruitment and activation of Tec family kinases in human neutrophils. II. Effects of LFM-A13, a specific Btk inhibitor.
    Gilbert C; Levasseur S; Desaulniers P; Dusseault AA; Thibault N; Bourgoin SG; Naccache PH
    J Immunol; 2003 May; 170(10):5235-43. PubMed ID: 12734372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A dual function anti-leukemic agent with anti-thrombotic activity.
    Tibbles H; Vassilev A; Uckun FM
    Leuk Lymphoma; 2002 May; 43(5):1121-7. PubMed ID: 12148895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bruton's tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex.
    Vassilev A; Ozer Z; Navara C; Mahajan S; Uckun FM
    J Biol Chem; 1999 Jan; 274(3):1646-56. PubMed ID: 9880544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of Bruton tyrosine kinase inhibition on chemotaxis and superoxide generation in human neutrophils.
    Broides A; Hadad N; Levy J; Levy R
    J Clin Immunol; 2014 Jul; 34(5):555-60. PubMed ID: 24771458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.
    Bam R; Ling W; Khan S; Pennisi A; Venkateshaiah SU; Li X; van Rhee F; Usmani S; Barlogie B; Shaughnessy J; Epstein J; Yaccoby S
    Am J Hematol; 2013 Jun; 88(6):463-71. PubMed ID: 23456977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.